VRTIX - Vanguard Russell 2000 Index Fund Institutional Shares This fund is a listed as child fund of Vanguard Group Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value IWO - iShares Russell 2000 Growth ETF This fund is a listed as child fund of BlackRock Inc. Momentum Factor ETF ETF Shares This fund is a listed as child fund of Vanguard Group Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value JETSX - Total Stock Market Index Trust NAV SMXAX - SIIT Extended Market Index Fund - Class A This representsĭWAS - Invesco DWA SmallCap Momentum ETF This fund is a listed as child fund of Invesco Ltd. The share price as of Septemis 15.75 / share. Schedule 13G indicates a passive investment of over 5%. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. ĤD Molecular Therapeutics Inc (NASDAQ:FDMT) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Viking Global Investors Lp, Bvf Inc/il, Ra Capital Management, L.p., VR Adviser, LLC, BlackRock Inc., Janus Henderson Group Plc, Deep Track Capital, LP, State Street Corp, Vanguard Group Inc, and Morgan Stanley. These institutions hold a total of 43,467,817 shares. NOTV has returned 37.7% in the past month.4D Molecular Therapeutics Inc (US:FDMT) hasĢ37 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). (NOTV), another stock in the same industry, closed the last trading session 3.7% higher at $5.84. is part of the Zacks Medical - Drugs industry. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >ĤD Molecular Therapeutics, Inc. The stock currently carries a Zacks Rank #3 (Hold). So, make sure to keep an eye on FDMT going forward to see if this recent jump can turn into more strength down the road. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.įor 4D Molecular Therapeutics, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Revenues are expected to be $1.45 million, up 19.1% from the year-ago quarter. Expected earnings in the upcoming report, represents a year-over-year change of -7.3%.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |